Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Calcineurin–Nuclear factor of activated T-cells (NFAT) signaling complex is a central regulator of the immune response, specifically within T lymphocytes [2], [14]. Calcineurin, a calcium-dependent serine/threonine phosphatase, is activated following T-cell receptor stimulation and subsequent calcium influx [10], [17]. Once active, it dephosphorylates NFAT transcription factors, enabling their translocation from the cytoplasm to the nucleus [6], [20]. In the nucleus, NFAT binds to the promoters of various genes, most notably interleukin-2 (IL-2), to drive T-cell activation, proliferation, and differentiation [11], [17]. This pathway is a cornerstone of the adaptive immune system but is also implicated in the pathogenesis of autoimmune diseases and the rejection of transplanted organs [4], [13]. Therapeutically, the Calcineurin–NFAT complex is targeted by calcineurin inhibitors (CNIs) such as cyclosporine A and tacrolimus [1], [3]. These drugs bind to intracellular immunophilins to form a complex that sterically blocks calcineurin’s active site, preventing NFAT dephosphorylation and subsequent cytokine production [11], [12]. While CNIs are essential for modern transplantation medicine and the management of conditions like psoriasis and rheumatoid arthritis, their use is limited by a narrow therapeutic window [3], [8]. Notable safety concerns include dose-dependent nephrotoxicity, neurotoxicity, and an increased risk of opportunistic infections or malignancies [1], [7], [10]. Ongoing research aims to develop more selective inhibitors that disrupt the specific interaction between calcineurin and NFAT without affecting other calcineurin-dependent cellular processes [16], [18].
Inhibition of calcineurin phosphatase activity, preventing dephosphorylation and nuclear translocation of NFAT, thereby suppressing cytokine gene expression [2], [6], [9].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcineurin–Nuclear factor of activated T-cells signaling complex (CaN-NFAT complex) (CaN-NFAT complex).